| abstract |
Compounds according to Formula I: n nor a pharmaceutically acceptable salt thereof wherein: A 1 is NR 1 or CR 1 , with R 1 being H or methyl, with methyl, if present, optionally being substituted with one or more F; the cyclopropyl moiety can be optionally substituted with one or more methyl and one or more F; A 2 -A 5 are N or CR 2 -CR 5 , respectively, with the proviso that no more than two of the four positions A in A 2 -A 5 can be simultaneously N; R 2 -R 5 are independently H, halogen, amino, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl; R 6 and R 7 are independently H, F, methyl, ethyl, hydroxyl or methoxy or R 2 and R 3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F; R 8 is H or C(1-6)alkyl; R 9 is selected from the group consisting of Formula II, III, IV and Vn n n n n n n n n n n The compounds can be used as inhibitors of RORγ and are useful for the treatment of RORγ mediated diseases. |